AI-generated content for informational purposes only. Not financial advice. Always do your own research.

关于

Becton Dickinson is a global medical technology company that manufactures syringes, needles, diagnostic instruments, medication management systems, and laboratory equipment used by healthcare institutions worldwide. The company is a Dividend Aristocrat with over 50 consecutive years of dividend increases, reflecting its durable competitive advantages and essential product portfolio. BDX attracts income-oriented investors who want reliable exposure to the healthcare sector.

蓝筹股票

凭借超过一个世纪的运营历史、覆盖全球几乎每个国家医疗机构的全球配送网络,以及持续的收益增长,Becton Dickinson是医疗技术领域的可靠蓝筹股。

股息股票

Becton Dickinson是一家股息贵族公司,拥有超过50年连续增加年度股息的历史,其支持基础是非自由裁量性医疗用品的非自由裁量性质,这些产品在任何经济环境下都能产生稳定的现金流。

医疗保健股票

Becton Dickinson供应全球医院和诊所日常依赖的注射器、针头、输液导管、诊断系统和药物管理平台,使其成为必不可少的医疗保健股票。

Key Financials BDX

价格 $175.89
变化(1天) -1.08%
变化 (30D) +15.28%
变化 (60D) +17.15%
变化 (90D) +16.53%
变化 (180D) +29.32%
变化 (1Y) -0.94%
变化 (5Y) -9.77%
P/E比率 12.65
EPS (TTM) $13.90
52周区间 $127.59 — $185.02
50日MA $159.08
成交量 3.17M

Data updated Feb 15 · Source: Twelve Data

4.1
2 reviews
Market Position
4.7
Dividend Reliability
4.2
Valuation Attractiveness
4
Financial Stability
3.3
Management Quality
3.2
Long-Term Growth
2.5
Claude Opus 4.6
AI Review
3.7/5

Becton Dickinson is a global medical technology leader specializing in medical devices, instrument systems, and reagents. The company holds dominant positions in syringes, needles, and diagnostic systems, providing a durable competitive moat. At a P/E of 12.65 with EPS of $13.90, BDX appears attractively valued relative to healthcare peers, though this may reflect market concerns about growth trajectory.

The bull case centers on BD's essential product portfolio, recurring revenue streams, and recent strong momentum " up 29% over six months with the stock trading well above its 50-day moving average. The planned separation of its Biosciences segment could unlock shareholder value.

However, the bear case is notable: the stock is down nearly 10% over five years, significantly underperforming the broader market. Integration challenges from the Alaris infusion pump recall and elevated debt from acquisitions remain headwinds. The dividend yield, while supported by a 50+ year growth streak, is modest. BD offers defensive healthcare exposure but has struggled to deliver meaningful capital appreciation, making it better suited for income-oriented, conservative portfolios.

Market Position
4.7
Dividend Reliability
4.2
Valuation Attractiveness
4
Financial Stability
3.3
Management Quality
3.2
Long-Term Growth
2.5
Feb 15, 2026
Gemini 3 Pro Preview
AI Review
4.5/5

Becton Dickinson (BDX) remains a cornerstone of the medical technology sector, providing essential consumables and diagnostic systems that create a wide economic moat. Currently trading significantly below its 52-week high and well under its 50-day moving average, the stock presents a potential value opportunity for contrarian investors. With a P/E ratio of approximately 13, BDX is priced attractively compared to historical norms and broader healthcare indices, suggesting the market has priced in significant pessimism. While the company faces near-term headwinds regarding margins and operational execution, its status as a Dividend Aristocrat underscores its financial resilience and long-term commitment to shareholder returns. For investors seeking a defensive healthcare play with reliable cash flows and limited downside risk at this valuation, BDX offers a compelling entry point, though patience may be required for a technical trend reversal.

Feb 12, 2026